Role of molecular markers in the diagnosis and therapy of renal cell carcinoma

Urology

Volumn 66, Issue 5 SUPPL., 2005, Pages 1-9

  Lam, John S ^a   Leppert, John T ^a   Figlin, Robert A ^a   Belldegrun, Arie S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBONATE DEHYDRATASE; CHEMOKINE RECEPTOR CXCR4; EPIDERMAL GROWTH FACTOR; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MOLECULAR MARKER; SOMATOMEDIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ALGORITHM; ANGIOGENESIS; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE MARKER; GENE EXPRESSION PROFILING; GENE MUTATION; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; METASTASIS; MOLECULAR MODEL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME; WORLD HEALTH ORGANIZATION;

EID: 25144442538     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2005.06.112     Document Type: Article

References (43)

1. A. Jemal, T. Murray, E. Ward Cancer statistics, 2005 CA Cancer J Clin 55 2005 10 30
2. W.H. Chow, S.S. Devesa, J.L. Warren Rising incidence of renal cell cancer in the United States JAMA 281 1999 1628 1631
3. J.S. Lam, J.T. Leppert, R.A. Figlin Surveillance following radical or partial nephrectomy for renal cell carcinoma Curr Urol Rep 6 2005 7 18
4. J.S. Lam, O. Shvarts, J.T. Leppert Renal cell carcinoma 2005 new frontiers in staging, prognostication, and targeted molecular therapy J Urol 173 2005 1853 1862
5. J.S. Lam, A.S. Belldegrun, R.A. Figlin Advances in immune-based therapies of renal cell carcinoma Expert Rev Anticancer Ther 4 2004 1081 1096
6. R.J. Motzer, M. Mazumdar, J. Bacik Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17 1999 2530 2540
7. A. Zisman, A.J. Pantuck, F. Dorey Improved prognostication of renal cell carcinoma using an integrated staging system J Clin Oncol 19 2001 1649 1657
8. M.W. Kattan, V. Reuter, R.J. Motzer A postoperative prognostic nomogram for renal cell carcinoma J Urol 166 2001 63 67
9. I. Frank, M.L. Blute, J.C. Cheville An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis the SSIGN score J Urol 168 2002 2395 2400
10. T.M. Mekhail, R.M. Abou-Jawde, G. Boumerhi Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma J Clin Oncol 23 2005 832 841
11. A. Zisman, A.J. Pantuck, R.A. Figlin Validation of the UCLA integrated staging system for patients with renal cell carcinoma J Clin Oncol 19 2001 3792 3793
12. J.W. Slaton, A. Zisman, A. Belldegrun Validation of UCLA integrated staging system (UISS) as a predictor for survival in patients undergoing nephrectomy for renal cell carcinoma J Urol 167 2002 192
13. K.R. Han, I. Bleumer, A.J. Pantuck Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population J Urol 170 2003 2221 2224
14. J.J. Patard, H.L. Kim, J.S. Lam Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma an international multicenter study J Clin Oncol 22 2004 3316 3322
15. A. Zisman, A.J. Pantuck, J. Wieder Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma J Clin Oncol 20 2002 4559 4566
16. S.A. Fuhrman, L.C. Lasky, C. Limas Prognostic significance of morphologic parameters in renal cell carcinoma Am J Surg Pathol 6 1982 655 663
17. A.L. Harris Hypoxia - a key regulatory factor in tumour growth Nat Rev Cancer 2 2002 38 47
18. G.L. Semenza HIF-1 and tumor progression pathophysiology and therapeutics Trends Mol Med 8 suppl 2002 S62 S67
19. P.H. Maxwell, M.S. Wiesener, G.W. Chang The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis Nature 399 1999 271 275
20. M. Ohh, C.W. Park, M. Ivan Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein Nat Cell Biol 2 2000 423 427
21. C.P. Pavlovich, L.S. Schmidt Searching for the hereditary causes of renal-cell carcinoma Nat Rev Cancer 4 2004 381 393
22. S. Ivanov, S.Y. Liao, A. Ivanova Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer Am J Pathol 158 2001 905 919
23. K. Grabmaier, J.L. Vissers, M.C. De Weijert Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250 Int J Cancer 85 2000 865 870
24. R. Opavsky, S. Pastorekova, V. Zelnik Human MN/CA9 gene, a novel member of the carbonic anhydrase family structure and exon to protein domain relationships Genomics 33 1996 480 487
25. E. Oosterwijk, D.J. Ruiter, P.J. Hoedemaeker Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney Int J Cancer 38 1986 489 494
26. S.Y. Liao, O.N. Aurelio, K. Jan Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney Cancer Res 57 1997 2827 2831
27. H. Uemura, Y. Nakagawa, K. Yoshida MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas Br J Cancer 81 1999 741 746
28. E. Oosterwijk, N.H. Bander, C.R. Divgi Antibody localization in human renal cell carcinoma a phase I study of monoclonal antibody G250 J Clin Oncol 11 1993 738 750
29. C.R. Divgi, N.H. Bander, A.M. Scott Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma Clin Cancer Res 4 1998 2729 2739
30. I. Bleumer, A. Knuth, E. Oosterwijk A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients Br J Cancer 90 2004 985 990
31. M.H. Bui, D. Seligson, K.R. Han Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma implications for prognosis and therapy Clin Cancer Res 9 2003 802 811
32. M. Atkins, D. McDermott, J. Mier Carbonic anhydrase IX (CAIX) expression predicts for renal cell cancer (RCC) patient response and survival to IL-2 therapy Proc Am Soc Clin Oncol 23 2004 383 Abstract 4512
33. J.S. Lam, A.S. Belldegrun, R.A. Figlin Tissue array-based predictions of pathobiology, prognosis, and response to treatment for renal cell carcinoma therapy Clin Cancer Res 10 suppl 2004 6304S 6309S
34. J.R. Vasselli, J.H. Shih, S.R. Iyengar Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor Proc Natl Acad Sci U S A 100 2003 6958 6963
35. M.H. Tan, C.G. Rogers, J.T. Cooper Gene expression profiling of renal cell carcinoma Clin Cancer Res 10 suppl 2004 6315S 6321S
36. H.L. Kim, D. Seligson, X. Liu Molecular prognostic modeling using protein expression profile in clear cell renal carcinoma J Urol 171 2004 436
37. M. Takahashi, D.R. Rhodes, K.A. Furge Gene expression profiling of clear cell renal cell carcinoma gene identification and prognostic classification Proc Natl Acad Sci U S A 98 2001 9754 9759
38. H.L. Kim, D. Seligson, X. Liu Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma J Urol 173 2005 1496 1501
39. J.C. Yang, L. Haworth, R.M. Sherry A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 2003 427 434
40. J.T. Leppert, J.S. Lam, H. Yu Targeting the vascular endothelial growth factor pathway in renal cell carcinoma, a tissue array based analysis J Clin Oncol 23 suppl 2005 386S
41. F. Fan, J.S. Wey, M.F. McCarty Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells Oncogene 24 2005 2647 2653
42. J.S. Lam, J.T. Leppert, H. Yu Expression of the vascular endothelial growth factor family in tumor dissemination and disease free survival in clear cell renal cell carcinoma J Clin Oncol 23 suppl 2005 387S
43. A.J. Pantuck, D.B. Seligson, H. Wu Characterization of the mTOR pathway in renal cell carcinoma and its use in predicting patient selection for agents targeting this pathway J Urol 173 suppl 2005 96